---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-006649"
form_type: "8-K"
ticker: "PTIX"
cik: "0001022899"
company_name: "Protagenic Therapeutics, Inc.new"
filed_at: "2025-04-29T23:59:59+00:00"
generated_at: "2026-05-23T03:19:40.429345+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Protagenic Therapeutics approves 1-for-14 reverse stock split effective May 5, 2025

## Summary
- Reverse stock split at 1-for-14 ratio, effective 12:01 a.m. ET on May 5, 2025.
- Intended to bring PTIX into compliance with Nasdaq minimum bid price rule 5550(a)(2).
- Share count to drop from ~8.24M to ~588,750; fractional shares rounded up.
- Stockholders approved split on April 18, 2025 with ratio range 1:10 to 1:20; board set at 1:14.
- Symbol PTIX unchanged; new CUSIP 74365N301; no change in authorized shares.

## SEC filing metadata
- accession: 0001641172-25-006649
- form_type: 8-K
- ticker: PTIX
- cik: 0001022899
- company_name: Protagenic Therapeutics, Inc.new
- filed_at: 2025-04-29T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1022899/000164117225006649/0001641172-25-006649-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1022899/000164117225006649/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-006649
- JSON: https://secwatch.observer/filing/0001641172-25-006649.json
- Plain text: https://secwatch.observer/filing/0001641172-25-006649.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.